Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury

TEL AVIV, Israel, June 22, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered tissue implants for spinal cord injury, announced the initiation of a pivotal preclinical efficacy study evaluating its engineered human neural...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.